Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

August 2017

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors

June 2017

A phase 1, multicenter, dose-escalation Study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations

May 2017

A Pilot Study of the Efficacy of a Bruton’s Tyrosine Kinase Inhibitor in the Treatment of Dogs with Pemphigus Foliaceus

April 2017

PRN1371, an irreversible, covalent inhibitor of FGFR1-4 exhibits sustained pathway inhibition in cancer cell lines

April 2016

PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models

March 2016

A New Treatment for Autoimmune Blistering Diseases:  Efficacy of the Bruton’s Tyrosine Kinase (BTK) Inhibitor PRN473 in Canine Pemphigus Foliaceus

March 2016

Development of PRN1008, a novel, reversible covalent BTK inhibitor in clinical development for pemphigus

March 2016

A New Treatment for Autoimmune Blistering Diseases: Efficacy of the Bruton’s Tyrosine Kinase (BTK) Inhibitor PRN473 in Canine Pemphigus Foliaceus

Advancing Promising Therapies

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website